Implicit and Explicit Assessment of Suicide Risk

NCT05903469 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2025-05-29

No results posted yet for this study

Summary

In 2007 Nock \& Banaji developed a so-called implicit suicide risk measurement using a computer tool: the Implicit Association Test (IAT). This measurement, associated with traditional evaluations, makes it possible to better predict suicidal recurrence. In 2020, the Poitiers team of Tello was able to replicate these results on a French population. However, although a high IAT score predicts the onset of suicide at 1 year, there is no data on how this score changes over time nor even data concerning the measure's ability to differentiate a population with explicit suicidal ideation from a population without explicit suicidal ideation. The investigators therefore seek to demonstrate an evolution of implicit suicidal ideation over time by replicating the measurement at inclusion, at 6 months and at 12 months, for different patient profiles: Suicidal ideation vs No suicidal ideation and suicide attempt vs no suicide attempt. Patients will be recruited from the emergency-unit of CHU Amiens-Picardie and will take the suicide-IAT as well as various questionnaires.

Conditions

  • Implicit Association Test
  • Suicide
  • Prevention, Suicide
  • Suicide Risk Factor

Interventions

OTHER

Implicit Attitude Test

The IAT (Implicit Attitude Test) is a method of indirectly measuring the relative strength of associations between different concepts stored in memory based on reaction times on computer. The general idea behind this measure is that an individual will be much faster to categorize an object into a predetermined category, if this categorization is consistent with their own way of processing information.

Sponsors & Collaborators

  • Centre Hospitalier Pinel d'Amiens

    collaborator UNKNOWN
  • Centre Hospitalier Universitaire, Amiens

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-28
Primary Completion
2025-12-31
Completion
2026-01-31

Countries

  • France

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05903469 on ClinicalTrials.gov